Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin a shown to protect tiny Preemies' lungs

NCT ID NCT07577180

Disease control Sponsor: Erhan Calisici Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving very low birth weight preterm infants (born at or before 32 weeks, weighing under 1250 grams) a weekly high-dose oral vitamin A supplement could reduce their risk of developing bronchopulmonary dysplasia (BPD), a chronic lung disease. The trial randomly assigned 209 babies to receive either the vitamin or standard care. The goal was to see if this simple, low-cost approach could lower the number of infants needing oxygen at 36 weeks and improve overall outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

209 people

The number who actually took part.

Started

Mar 2012

Finished

Mar 2013

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 days and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Preterm infants with gestational age ≤32 weeks * Birth weight ≤1250 grams * Admitted to the neonatal intensive care unit * Initiated enteral feeding within the first days of life Exclusion Criteria: * Major congenital anomalies * Chromosomal abnormalities * Severe perinatal asphyxia * Inborn errors of metabolism * Infants who died before initiation of enteral feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchopulmonary dysplasia (BPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Premature Birth bronchopulmonary dysplasia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bronchopulmonary dysplasia (BPD) Prematurity Very low birth weight

Contacts and locations

Locations

  • Kocaeli City Hospital

    Köseköy, Kocaeli, 41060, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.